Superworth

Beam Therapeutics profit margin BEAM

Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.

Net margin, 12 months
−73.0%
Peer median
20.4%

Over the twelve months to Sep 30, 2026, Beam Therapeutics kept −73.0% of its revenue as net profit.

The median for 10 biotech stocks of a similar size is 20.4%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−56.3%n/a
FY2024n/an/a
FY2023−35.1%−46.7%
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q3 FY26−73.0%n/an/a
Q2 FY26−54.6%n/an/a
Q1 FY26−39.5%n/an/a
Q4 FY25−56.3%n/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24−41.1%n/a−52.2%
Q2 FY24−40.6%n/a−52.3%
Q1 FY24−37.3%n/a−50.3%
Q4 FY23−35.1%n/a−46.7%

Against its peers

Companies in Biotechnology nearest Beam Therapeutics' size, closest first, today.

Where Beam Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Beam Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.